Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF +1.12%30 3-Year Book Growth Rate is -42.10% as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 30/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 762 Medical Devices & Instruments companies, Acarix AB ranks worse than 92.65% on this metric.
During the past 12 months, Acarix AB's average Book Value per Share Growth Rate was -41.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -42.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -41.10% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -31.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Acarix AB was 104.20% per year. The lowest was -46.00% per year. And the median was -42.10% per year.
Acarix AB (OTCPK:ACIXF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Acarix AB 3-Year Book Growth Rate Related Terms
ACIXF vs ABT, SYK, MDT: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, Acarix AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Acarix AB's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -42.10% mean?
Acarix AB (ACIXF) has a 3-Year Book Growth Rate of -42.10% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #706 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 92.7%.
Is Acarix AB's 3-Year Book Growth Rate too high?
Acarix AB's current 3-Year Book Growth Rate is -42.10%. Based on the distribution chart, Acarix AB ranks #706 out of 762 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Acarix AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 3-Year Book Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #706 out of 762 companies for 3-Year Book Growth Rate. This places Acarix AB in the lower half of its industry. The industry median 3-Year Book Growth Rate is 2.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.35, based on 762 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current 3-Year Book Growth Rate is -42.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 40% above its estimated fair value. The current 3-Year Book Growth Rate is -42.10%. Acarix AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Acarix AB (ACIXF), the current 3-Year Book Growth Rate is -42.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 40% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
3-Year Book Growth Rate: -42.10%
GF Value™: $0.02 vs. price of $0.03 (40% above fair value)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
30GF Score
Get the complete analysis for ACIXF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
